VERACYTE INC

VCYTNASDAQ

🏆 #1396 by market capEarnings Nov 3US Equity

$45.88▼ $0.52 (−1.14%)

Live

1h▼ 0.2%

24h▼ 1.1%

7d▼ 0.5%

14d▼ 17.6%

30d▼ 20.2%

1y▲ 59.5%

🏦Market Cap

$3.66B

Small Cap

📈Revenue Growth (YoY)

+16.0%

Healthy

📊Gross Margin

72.1%

High

💵FCF Margin

29.4%

Strong

⚖️P/S Ratio

6.6x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $45.72 – $46.57
52-Week Range: $27.79 – $60.91
Volume: $4.48B
Avg Volume: $5.15B
Shares Outstanding: 79.8M
Next Earnings: Sep 30, 2026

Fundamentals Snapshot

Annual Revenue: $517M
Last Q Revenue: $150M
P/E Ratio: 32.2
P/S Ratio: 6.6x
EPS (TTM): $1.44
Dividend Yield: 0.00%

Why Investors Own VCYT

✓High-growth profile — revenue up +51.7% YoY with expanding US Equity exposure.
✓Healthy economics — 68% gross margin and 17% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$517M▲ +57.3% YoY

Gross Margin (TTM)

67.7%▲ +0.9% YoY

Operating Income (TTM)

$74M▲ +57.3% YoY

Free Cash Flow (TTM)

$89M▲ +57.3% YoY

About VERACYTE INC

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

🦦